CB
CBLL.US CeriBell, Inc
- Market cap
- USD 1.02B
- P/E
- -
- P/B
- 8.72x
- ROE
- -68.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CBLL.US undervalued?
Graham numberThe Graham number of CeriBell, Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CeriBell, Inc fundamental analysis
No fundamental analysis for CeriBell, Inc yet.
CeriBell, Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CeriBell, Inc
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In …
Full company profileCeriBell, Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CeriBell, Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 25.9M | 45.2M | 65.4M | 89.1M | 112M |
| Gross Profit | 21.5M | 38.2M | 56.8M | 78.3M | 101M |
| Operating Income | -36.0M | -30.0M | -39.7M | -58.4M | -81.7M |
| EBITDA | -35.1M | -26.5M | -37.3M | -50.2M | -78.0M |
| Net Income | -37.2M | -29.5M | -40.5M | -53.4M | -80.5M |
| EPS | -1.59 | -1.26 | -1.13 | -1.46 | -2.09 |
| Balance Sheet | |||||
| Total Assets | 86.5M | 58.9M | 225M | 196M | 156M |
| Total Liabilities | 173M | 171M | 34.2M | 40.5M | 38.8M |
| Shareholders' Equity | -86.4M | -112M | 191M | 155M | 118M |
| Cash & Short-term Investments | 68.2M | 34.5M | 194M | 159M | 117M |
| Total Debt | 18.2M | 14.2M | 22.0M | 22.3M | 21.7M |
| Cash Flow | |||||
| Operating Cash Flow | -32.0M | -29.2M | -35.0M | -40.8M | -60.3M |
| Capital Expenditure | 516K | 983K | 1.34M | 767K | 3.34M |
| Free Cash Flow | -32.5M | -30.1M | -36.4M | -41.6M | -63.7M |
| Ratios | |||||
| ROE | - | - | -21.2% | -34.4% | -68.5% |
| ROA | -43.0% | -50.0% | -17.9% | -27.3% | -51.5% |
| Net Profit Margin | -143.4% | -65.1% | -61.8% | -60.0% | -71.9% |
| Debt to Equity | - | - | 0.11x | 0.14x | 0.18x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CeriBell, Inc dividends
CeriBell, Inc has not paid dividends in the last 4 fiscal years.
Who owns CeriBell, Inc
- Insiders 11.74%
- Institutions 88.27%
- Public & others 0.00%
- Shares outstanding 38.8M
- Free float 27.0M
Top funds holding CBLL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Small Cap Growth | 1.64M | 4.22% | 0.00% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.04M | 2.67% | +21.85% | Sep 2026 |
| Fidelity Stock Selector Small Cap | 1.02M | 2.64% | +2.20% | Aug 2026 |
| Federated Hermes Kaufmann Small Cap A | 939K | 2.42% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth K6 | 844K | 2.17% | +1.60% | Aug 2026 |
| Franklin Small Cap Growth Adv | 750K | 1.93% | 0.00% | Sep 2026 |
| Fidelity Series Small Cap Opps | 750K | 1.93% | +1.70% | Aug 2026 |
| iShares Russell 2000 ETF | 699K | 1.80% | 0.00% | Oct 2026 |
| Polar Capital Healthcare Opports Inc | 501K | 1.29% | 0.00% | Sep 2026 |
| Fidelity Select Medical Tech and Devcs | 425K | 1.10% | +0.09% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 417K | 1.07% | 0.00% | Sep 2026 |
| MFS New Discovery I | 370K | 0.95% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 301K | 0.78% | 0.00% | Aug 2026 |
| Royce Small-Cap Opportunity Invmt | 287K | 0.74% | +0.38% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 262K | 0.67% | -0.38% | Oct 2026 |
| FTGF RY US SmCp Opp A USD Dis(A) | 259K | 0.67% | -9.21% | Sep 2026 |
| Fidelity Growth Company Fund | 248K | 0.64% | 0.00% | Aug 2026 |
| Wasatch Micro Cap | 244K | 0.63% | 0.00% | Sep 2026 |
| BNP Paribas Health Cr Innovtr Cl Cap | 230K | 0.59% | +18.14% | Sep 2026 |
| BNP Paribas US Small Cap ClassicC | 221K | 0.57% | +1,288.82% | Sep 2026 |
Top institutions holding CBLL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 5.69M | 14.66% | +17.34% | Jun 2026 |
| TPG GP A, LLC | 3.76M | 9.69% | -5.20% | Jun 2026 |
| Red Tree Management, LLC | 2.21M | 5.68% | 0.00% | Sep 2026 |
| BlackRock Inc | 1.94M | 4.99% | +6.78% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.13M | 2.91% | -0.60% | Jun 2026 |
| KCM Capital Inc | 1.13M | 2.90% | -19.64% | Jun 2026 |
| Federated Hermes Inc | 940K | 2.42% | +0.01% | Jun 2026 |
| Franklin Templeton Inc | 918K | 2.36% | +13.44% | Jun 2026 |
| Adage Capital Partners Gp LLC | 900K | 2.32% | +18.93% | Jun 2026 |
| Bank of New York Mellon Corp | 896K | 2.31% | -22.77% | Jun 2026 |
| TimesSquare Capital Management, LLC | 783K | 2.02% | +0.30% | Sep 2026 |
| Millennium Management LLC | 727K | 1.87% | +31.74% | Jun 2026 |
| Geode Capital Management, LLC | 668K | 1.72% | +9.18% | Jun 2026 |
| Royce & Associates, LP | 605K | 1.56% | +17.31% | Jun 2026 |
| State Street Corp | 547K | 1.41% | +4.11% | Jun 2026 |
| Silvercrest Asset Management Group LLC | 469K | 1.21% | -4.27% | Jun 2026 |
| Massachusetts Financial Services Company | 390K | 1.00% | -23.37% | Jun 2026 |
| Redmile Group, LLC | 387K | 1.00% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 345K | 0.89% | +20.18% | Jun 2026 |
| Yu Fan | 342K | 0.88% | -37.68% | Jun 2026 |
CeriBell, Inc company profile
- Company name
- CeriBell, Inc
- Ticker
- CBLL.US
- Exchange
- USA Stocks
- Listed since
- Oct 11, 2024
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 327
- Fiscal year end
- December
- Address
- 360 North Pastoria Avenue, Sunnyvale, CA, United States, 94085
- Phone
- 800 436 0826
- Website
- ceribell.com
About CeriBell, Inc
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.
CeriBell, Inc management
10- Dr. Xingjuan Chao Ph.D.Co-Founder, President, CEO & Director · born 1980
- Dr. Josef Parvizi M.D., Ph.D.Co-Founder, Chief Medical Advisor & Director · born 1968
- Mr. Scott BlumbergChief Financial Officer
- Dr. Raymond Woo Ph.D.Chief Technology Officer · born 1982
- Mr. Marc GelnettSenior Vice President of Operations
- Ms. Kim McKeonVP of People & Culture
- Ms. Baharan Kamousi Ph.D.Senior Vice President of Data Science
- Mr. Joseph Sean ManniChief Revenue Officer · born 1974
- Mr. David FoehrSenior Vice President of Finance
- Alex Grant Ph.D.SVP of Engineering